Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK ‐air Study
Clinical & Experimental Allergy · 2026-08 · 56 (8) · 904-913
DOI: 10.1111/cea.70335 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 06.05.2026. Verfasst von Nuno Lourenço-Silva und 27 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Quality of Life, Rhinitis, Allergic, Anti-Allergic Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Allergic rhinitis displays a relevant impact on quality of life. Medications used in the treatment of rhinitis have been assessed on their impact on rhinoconjunctivitis‐related quality of life, but not on generic health‐related quality of life metrics, such as utilities or EQ‐5D visual analogue scale (VAS) levels. This study aimed to compare different medication classes and individual medications on utilities and EQ‐5D VAS levels using data from a mobile app.
Methods
We conducted an observational study using direct patient data from the MASK‐air mobile application, collected between May 2015 and December 2024. We compared rhinitis medication classes and individual medications on health utilities (computed from the EQ‐5D‐5L questionnaire) and the EQ‐5D VAS. To account for confounding, we employed inverse probability treatment weighting based on propensity scores, adjusting for demographics, baseline symptom control, and asthma status.
Results
The study analysed 69,973 observations with EQ‐5D VAS data and 842 observations with utility data. At the medication class level, fixed combinations of intranasal antihistamines and corticosteroids were associated with improvements in EQ‐5D VAS (mean difference = 1.900; 95% CI = 1.316–2.484) and utilities (mean difference = 0.022; 95% CI = −0.015 to 0.059) compared with oral antihistamines (OAH). Intranasal antihistamines were associated with lower EQ‐5D VAS and utility scores than other intranasal treatments. For individual medications, mometasone was associated with a lower EQ‐5D VAS than budesonide and fluticasone furoate, while fexofenadine and levocetirizine tended to be associated with lower VAS values than other OAH.
Conclusion
Fixed combinations of intranasal antihistamines and corticosteroids were associated with better quality‐of‐life than oral antihistamines and intranasal antihistamines. These findings could support future cost‐effectiveness analyses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.
- CINTESIS@RISE - Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
- Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.
- Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.
- Department of Cardiovascular and Respiratory Sciences, Porto Health School, Polytechnic Institute of Porto, Porto, Portugal.
- Department of Women's and Children's Health, Paediatric Research, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Nuno Lourenço-Silva, Bernardo Sousa-Pinto, Antonio Bognanni, Ana Margarida Pereira, João Coutinho-Almeida, Mattia Giovannini, Bilun Gemicioglu, Desiree E Larenas-Linnemann, Frederico S Regateiro, Sanna K Toppila-Salmi, Joaquin Sastre, Leticia de Las Vecillas, Ludger Klimek, Jean Bousquet, Rafael José Vieira
Zitieren
APA
Lourenço-Silva, N., Sousa-Pinto, B., Bognanni, A., Pereira, A. M., Coutinho-Almeida, J., Amaral, R., Brussino, L., Giovannini, M., Gemicioglu, B., Kvedariene, V., Larenas-Linnemann, D. E., Marques-Cruz, M., Papadopoulos, N. G., Pham-Thi, N., Regateiro, F. S., Toppila-Salmi, S. K., Samolinski, B., Sastre, J., Taborda-Barata, L., …, & Vieira, R. J. (2026). Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK ‐air Study. Clinical & Experimental Allergy, 56(8), 904-913. https://doi.org/10.1111/cea.70335
Vancouver
Lourenço-Silva N, Sousa-Pinto B, Bognanni A, Pereira AM, Coutinho-Almeida J, Amaral R, et al. Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK ‐air Study. Clinical & Experimental Allergy. 2026;56(8):904-913. doi:10.1111/cea.70335
BibTeX
@article{LourenoSilva2026,
author = {Lourenço-Silva, Nuno and Sousa-Pinto, Bernardo and Bognanni, Antonio and Pereira, Ana Margarida and Coutinho-Almeida, João and Amaral, Rita and Brussino, Luisa and Giovannini, Mattia and Gemicioglu, Bilun and Kvedariene, Violeta and Larenas-Linnemann, Desiree E and Marques-Cruz, Manuel and Papadopoulos, Nikolaos G and Pham-Thi, Nhân and Regateiro, Frederico S and Toppila-Salmi, Sanna K and Samolinski, Boleslaw and Sastre, Joaquin and Taborda-Barata, Luís and Valiulis, Arunas and Vecillas, Leticia de Las and Ventura, Maria Teresa and Pfaar, Oliver and Fonseca, João A and Zuberbier, Torsten and Klimek, Ludger and Bousquet, Jean and Vieira, Rafael José},
title = {Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK ‐air Study},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {8},
pages = {904--913},
doi = {10.1111/cea.70335}
}
EUVIMED